Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial.

[1]  N. Magné,et al.  Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[2]  M. Parmar,et al.  Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial , 2020, The Lancet.

[3]  M. Sydes,et al.  Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data , 2020, The Lancet.

[4]  H. G. van der Poel,et al.  Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. , 2020, European urology focus.

[5]  M. Graefen,et al.  External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort. , 2019, European urology.

[6]  Annette Haworth,et al.  Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans‐Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise , 2019, Journal of medical imaging and radiation oncology.

[7]  D. Low,et al.  Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial , 2018, International Journal of Radiation Oncology*Biology*Physics.

[8]  W. Lowrance,et al.  Impact of decipher test on adjuvant and salvage treatments received following radical prostatectomy. , 2018 .

[9]  T. Eade,et al.  The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study , 2018, The Journal of Nuclear Medicine.

[10]  H. G. van der Poel,et al.  EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. , 2017, European urology.

[11]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[12]  C. King.  The dose-response of salvage radiotherapy following radical prostatectomy: A systematic review and meta-analysis. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Shree Agrawal,et al.  Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Dubray,et al.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. , 2016, The Lancet. Oncology.

[15]  A. Kneebone,et al.  Optimizing Radiation Therapy Quality Assurance in Clinical Trials: A TROG 08.03 RAVES Substudy. , 2015, International journal of radiation oncology, biology, physics.

[16]  M. Cooperberg,et al.  Trends in Management for Patients With Localized Prostate Cancer, 1990-2013. , 2015, JAMA.

[17]  R. Uzzo,et al.  Low rates of adjuvant radiation in patients with nonmetastatic prostate cancer with high‐risk pathologic features , 2014, Cancer.

[18]  N. Willich,et al.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. , 2014, European urology.

[19]  L. Collette,et al.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) , 2012, The Lancet.

[20]  Markus Graefen,et al.  Systematic review and meta-analysis of studies reporting oncologic outcome after robot-assisted radical prostatectomy. , 2012, European urology.

[21]  S. Fosså,et al.  An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. , 2008, European journal of cancer.

[22]  Jeremy L Millar,et al.  Post-prostatectomy radiation therapy: consensus guidelines of the Australian and New Zealand Radiation Oncology Genito-Urinary Group. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[24]  C. N. Coleman,et al.  CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. , 2003, Seminars in radiation oncology.

[25]  I. Osterloh,et al.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. , 1997, Urology.

[26]  D. Osoba,et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. , 1993, Journal of the National Cancer Institute.

[27]  A. Zigmond,et al.  The Hospital Anxiety and Depression Scale , 1983, Acta psychiatrica Scandinavica.

[28]  A. D'Amico,et al.  ADJUVANT AND SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY: ASTRO/AUA GUIDELINE , 2013 .

[29]  C. Lawton.  Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical Trial , 2010 .

[30]  P. Carter,et al.  The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting , 2006, Prostate Cancer and Prostatic Diseases.